BioSpace News Archive

Kelvyn Cullimore, President and CEO of BioUtah, issued the following statement after the introduction of the Protect Medical Innovation Act, bipartisan legislation introduced by Senators Pat Toomey and Amy Klobuchar, to permanently repeal the medical device tax.

Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, officially opened the Company’s new Digital Technology Center in Bengaluru, India, a regional hub of digital and technology talent.

Santen Pharmaceutical Co., Ltd. announced on March 8 that as part of its initiatives to increase public awareness of glaucoma, it will sponsor activities to be conducted worldwide during World Glaucoma Week from March 10 to 16, 2019.

The National Sleep Foundation’s annual Sleep in America® poll shows that disciplined sleepers can afford the occasional shift of at least one-hour in their sleep schedules without paying the price the following day.

[08-March-2019] TARRYTOWN, N.Y. and PARIS , March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe

Radiation therapy system delivered to Korea’s Hallym University Kangnam Sacred Heart Hospital

Sedana Medical AB announced the results of the interim analysis for the company’s pivotal phase III study aimed at getting the candidate drug IsoConDa approved for inhalation sedation in intensive care in Europe.

Aldeyra Therapeutics, Inc., a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced year ended December 31, 2018 financial results.

Cerebral Therapeutics announced the closing of a $7.8 million Extension of its Series A financing by institutional investors Granite Point Capital Management, L.P., and Vivo Capital, LLC. This brings the total Series A investment to $11 million.